Legions quit weight-loss drugs within a year due to various factors such as cost, side effects, or limited coverage despite being viewed as lifelong treatments.
GLP-1 agonists aim to reduce complications from excess body fat by curbing hunger. Ozempic and Wegovy (semaglutide) target diabetes, overweight, and obesity.
[
add
]
[
|
|
...
]